Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Travere Therapeutics
ISIN US89422G1076
|WKN A2QHYP
Market cap (in EUR)
2,730 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 2,730 m |
| EPS, EUR | -0.98 |
| P/B ratio | 43.3 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 216 m |
| Net income, EUR | -296 m |
| Profit margin | -137.51% |
What ETF is Travere Therapeutics in?
There are 23 ETFs which contain Travere Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Travere Therapeutics is the L&G Pharma Breakthrough UCITS ETF.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.